Article Text
PostScript
Letters
Spectral-domain optical coherence tomography in subjects over 60 years of age, and its implications for designing clinical trials
Statistics from Altmetric.com
Footnotes
Contributors OC and CB wrote the article. PJP and CJD edited the OCT and statistical sections respectively.
Competing interests OC receives unrestricted research funding from Novartis. PJP has acted as a consultant for Heidelberg. CB and CJD have no competing interests.
Provenance and peer review Not commissioned; internally peer reviewed.